

line 13-65, and column 18, line 43 to column 19, line 8. When it comes to more specific guidance, the reference provides synthesis examples, which even broadly, do not disclose, e.g., teach or suggest, methods for the preparation of compounds that are claimed herein, particularly those having a bridging group corresponding to Y of the present claims. All 49 disclosed species in the reference lack such a bridging group. See the Examples of the reference, including table 1. Although the broad disclosure in the reference teaches that R<sup>5</sup> may be phenyl or napthyl substituted by groups which include phenoxy and naphthoxy, there is no direction to pair these groups with the heterocycles which are A as defined in claim 1 herein. Accordingly, the treatment methods claimed which employ these compounds are not obvious in view of this reference.

The examination should be extended to the full scope of claims 1-30 since the reference U.S. 6,080,763 was applied to all claims.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Csaba Henter, Reg. No. 50,908  
Richard J. Traverso, Reg. No. 30,595  
Attorneys for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
Arlington Courthouse Plaza I  
2200 Clarendon Boulevard, Suite 1400  
Arlington, Virginia 22201  
(703) 812-5331 [Direct Dial]  
E-mail address: henter@mwzb.com

**Filed: May 18, 2004**

K:\Bayer\12\P1\Reply May 04.doc